-
How Kinase Inhibitors Accelerate p38α Dephosphorylation
2026-09-19
A Brandeis University preprint shows that some kinase inhibitors do more than occupy the p38α active site: they reshape the activation loop so WIP1 can dephosphorylate its regulatory phospho-threonine more efficiently. The work introduces a conformational strategy for combining direct kinase inhibition with phosphatase-mediated signal termination, while highlighting important limits for translating purified-protein findings into cellular or disease models.
-
MG-132 Workflows for Proteasome and Apoptosis Studies
2026-09-19
MG-132, also known as Z-LLL-al, gives researchers a cell-permeable route to perturb proteasomal protein turnover while tracking apoptosis, cell-cycle behavior, ROS, and chromatin-associated responses. This guide combines dose-controlled workflows with a cautious extension of recent heterochromatin research into proteostasis and cancer assays.
-
Autophagy–Liver Metastasis Signature in Colorectal Cancer
2026-09-18
Bai et al. integrate bulk and single-cell transcriptomic analyses to create a six-gene prognostic signature linking autophagy, liver metastasis, and immune suppression in colorectal cancer. The study provides a framework for stratifying risk and interpreting immune-cell states, while its computational and retrospective design requires prospective and functional validation.
-
Bestatin Hydrochloride: A Mechanistic Assay Guide
2026-09-18
Bestatin hydrochloride (Ubenimex) is more than a general aminopeptidase inhibitor: it can reveal how peptide processing shapes neuronal and angiogenic phenotypes. This guide connects a classic neurophysiology study with modern assay design, target interpretation, and research-use limitations.
-
Ro 3306: CDK1 Inhibitor Workflow Guide
2026-09-17
Ro 3306 enables controlled CDK1 inhibition for cell cycle G2/M phase arrest, cancer cell synchronization, and phase-resolved DNA repair experiments. This guide connects practical inhibitor workflows with mTORC1 cell-cycle dynamics to improve assay timing, controls, and interpretation.
-
Alpha-Ketoglutarate: The Metabolic–Immune Lever
2026-09-17
A translational perspective on how alpha-ketoglutarate connects TCA-cycle flux, nitrogen handling, and macrophage immune function. Drawing on a 2025 cholangiocarcinoma study, this article outlines experimental strategies for testing the PDHA1–α-KGA–OXGR1 axis and using a defined research reagent to move from metabolic observation toward mechanism.
-
LPS Protection of Macrophages Against Antitumor Drugs
2026-09-16
The reference study identifies system Xc−, glutathione production, and ABCC1-associated transport as contributors to lipopolysaccharide-mediated protection of macrophages from antitumor drug injury. Its findings clarify why MK-571 can be mechanistically informative in transporter assays, while also showing that its macrophage effects should not be interpreted solely through leukotriene receptor pharmacology.
-
Dovitinib (TKI-258, CHIR-258) Assay Guide
2026-09-15
A scenario-based guide to using Dovitinib (TKI-258, CHIR-258), SKU A2168, in cell viability, proliferation, and apoptosis experiments. It connects low-nanomolar RTK pharmacology with practical stock preparation, assay compatibility, pathway validation, and vendor-selection criteria.
-
Transcription Condensates Safeguard Genome Stability
2026-09-15
The reference study identifies a cell-cycle timer that forms transcription condensates at histone locus bodies during the G1/S transition and removes them in mid-S phase through ATR-CHK1 signaling. This mechanism links linker histone expression to DNA replication and shows why failed condensate resolution can produce genome-wide DNA damage.
-
Brain-to-Spinal Control of Mechanical Allodynia
2026-09-14
The reference study identifies a contralateral lPBN Oprm1–dmH Pdyn–spinal dorsal horn pathway that regulates both the laterality and persistence of mechanical allodynia in mice. Its projection-defined perturbations show how descending inhibitory control can prevent contralateral pain hypersensitivity after nerve injury and shorten bilateral hypersensitivity after capsaicin exposure.
-
GLP-1 (9-36) Amide in Receptor Assays
2026-09-14
GLP-1 (9-36) amide is a glucagon-like peptide-1 receptor antagonist for dissecting cAMP-linked GPCR signaling. This guide moves beyond product description to show how assay architecture, receptor crosstalk, peptide handling, and orthogonal controls affect interpretation.
-
BI 2536 PLK1 Inhibitor: Workflow Guide
2026-09-13
BI 2536 combines subnanomolar PLK1 potency with a practical workflow for dissecting mitotic arrest, checkpoint control, and tumor-cell death. This guide connects dose-response experiments to the p31comet–TRIP13 checkpoint mechanism and highlights formulation, assay, and xenograft-model considerations.
-
Lovastatin Workflows for HMG-CoA Reductase Research
2026-09-12
Lovastatin connects mevalonate-pathway inhibition with practical assays for proliferation, apoptosis, wound remodeling, and macrophage efferocytosis. This workflow-focused guide explains solvent handling, dose design, model selection, and troubleshooting for reproducible HMG-CoA reductase research.
-
Rucaparib in DNA Damage Response Research
2026-09-12
Rucaparib (AG-014699) is a practical PARP1-directed tool for connecting DNA repair defects, radiation response, and cell-death phenotypes in cancer models. This workflow combines controlled compound handling with orthogonal DNA-damage and transcriptional readouts to distinguish repair failure from loss of transcription.
-
BIIE 0246: Y2R Antagonist Workflows
2026-09-11
BIIE 0246 enables selective interrogation of neuropeptide Y Y2 receptor signaling across synaptic, gastrointestinal, metabolic, and behavioral assays. This workflow-focused guide shows how to separate Y2R biology from the Y1R-centered adipose-neural arrhythmia pathway and optimize concentration, timing, controls, and interpretation.